Genzyme Corp. sells off its diagnostics business to Sekisui Chemical Co. Ltd. for $265 million in cash. Genzyme Corp. (NSDQ:GENZ) is planning to sell off its diagnostics business to Tokyo-based ...
Sanofi-aventis CEO Chris Viebacher outlined the research and development strategy that led to the <a target="_blank" href="http://www.masshightech.com/stories/2011/02 ...
How do you whittle 35 years of headlining business news down to a couple thousand words and a few pages? You don't. But here, we take our best shot to highlight the companies, individuals, and moments ...
BOSTON, May 26 (Reuters) - Activist investor Carl Icahn said he will ask the board of biotechnology company Genzyme Corp to consider removing Chief Executive Henri Termeer from his post as chairman of ...
On July 26, 2024, Genzyme Corp. (a wholly owned subsidiary of Sanofi) filed suit in the District Court for the District of Delaware against Sarepta Therapeutics, Inc., and Sarepta Therapeutics Three, ...
The US has faced numerous issues involving prescription drugs, especially with rising costs and accessibility of life-saving and required medications. One class action lawsuit (Wilkins et. al. v.
Genzyme Corp. and Dyax Corp. have ended a collaboration on their development of a drug called DX-88. Dyax said it will receive all the assets of the joint venture, full ownership of the drug, and a ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Genzyme Corp.’s partner Hospira Inc. (NYSE: HSP) has ...
BOSTON (CBS.MW) -- Genzyme Corp. swung to a third-quarter net loss because of acquisition charges, but sales soared 60 percent on growth of a key kidney dialysis medication, the biotech firm reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results